Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1628
This examiner grants 67% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18005364 | MAVOGLURANT, A MGLUR5 ANTAGONIST, FOR USE IN THE TREATMENT IN THE REDUCTION OF OPIOID USE | Final Rejection | Novartis AG |
| 19236838 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | Final Rejection | AXSOME THERAPEUTICS, INC. |
| 19169261 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | Non-Final OA | AXSOME THERAPEUTICS, INC. |
| 18650053 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | Non-Final OA | AXSOME THERAPEUTICS, INC. |
| 18512551 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | Non-Final OA | AXSOME THERAPEUTICS, INC. |
| 18503996 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | Non-Final OA | AXSOME THERAPEUTICS, INC. |
| 18366992 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | Non-Final OA | AXSOME THERAPEUTICS, INC. |
| 17832911 | Immunomodulation by IAP Inhibitors | Non-Final OA | DANA-FARBER CANCER INSTITUTE, INC. |
| 17908999 | MODIFIED TETRACYCLINES FOR TREATMENT OF ALCOHOL USE DISORDER, PAIN AND OTHER DISORDERS INVOLVING POTENTIAL INFLAMMATORY PROCESSES | Final Rejection | Texas Tech University System |
| 18376127 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 18107336 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 18866127 | OLFACTORY RECEPTOR 2A4/7 AGONIST FOR PROMOTING HAIR GROWTH AND IMPROVING AESTHETIC ASPECT | Final Rejection | GIULIANI S.P.A. |
| 17910385 | METHOD FOR TREATING CHRONIC KIDNEY DISEASES | Final Rejection | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) |
| 17820773 | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS | Non-Final OA | Vertex Pharmaceuticals Incorporated |
| 18454012 | METHODS FOR INHIBITING MUSCLE ATROPHY | Non-Final OA | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS |
| 18195296 | Method for Reducing Ototoxicity in Pediatric Patients Receiving Plantinum-Based Chemotherapy | Non-Final OA | The United States Government as represented by The Department of Veterans Affairs |
| 18212115 | Dissolved Protein Arthritis Markers | Non-Final OA | The University of British Columbia |
| 18330163 | ASSAY TO IDENTIFY ANTI-CANCER AGENTS | Non-Final OA | LDN Pharma Limited |
| 18554869 | PLATINUM/PEPTIDE/CUCURBITURIL COMPLESES: WELL-DEFINED ARCHITECTURES BUILT BY SUPRAMOLECULAR SELF-SORTING FOR THE TARGETING OF CYSTEINE PROTEASES | Non-Final OA | Ohio University |
| 18530198 | TERPENE-BASED COMPOSITIONS, PROCESSES, METHODOLOGIES FOR CREATION AND PRODUCTS THEREBY | Non-Final OA | Scientific Holdings, LLC |
| 18529898 | COMPOSITIONS AND METHODS FOR TREATING BRAIN-GUT DISORDERS | Non-Final OA | Enterin, Inc. |
| 18526732 | TREATMENT OF NEUROLOGICAL DISORDERS | Non-Final OA | UNIVERSITÄT BASEL |
| 18565725 | FUSED HETEROCYCLIC DERIVATIVES | Non-Final OA | Janssen Sciences Ireland Unlimited Company |
| 18518267 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | Final Rejection | ARDELYX, INC. |
| 18511931 | METHOD OF PREPARING 1-(2,2-DIMETHYLPROPYL)-CYCLOPROPENE AS SPRAYABLE ETHYLENE ANTAGONIST IN PLANTS AND USES THEREOF | Non-Final OA | KYUNG SANG NAM DO |
| 18511243 | LIPID COMPOSITIONS | Non-Final OA | Aker BioMarine Antarctic AS |
| 18560663 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | Non-Final OA | Bridge Medicines |
| 18274314 | HETEROAROMATIC PHOSPHONIUM SALTS AND THEIR USE TREATING CANCER | Non-Final OA | FLORATEK PHARMA S.A. |
| 18216057 | OXYSTEROLS AND METHODS OF USE THEREOF | Final Rejection | Sage Therapeutics, Inc. |
| 18488169 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | Non-Final OA | Acerta Pharma B.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy